BioSpace News Archive

REGENXBIO Inc. (Nasdaq: RGNX) today announced positive interim data from the Phase II AAVIATE® trial of ABBV-RGX-314 for the treatment of wet age-related macular degeneration (wet AMD) using suprachoroidal delivery. Wet AMD is a chronic, life-long disease with available anti-VEGF treatment options that may reduce the risk of blindness, but require frequent injections.

Inhibikase Therapeutics, Inc. today announced that Joseph Frattaroli, Chief Financial Officer, plans to retire at the end of the first quarter of 2024.

Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960), (“Braxia Scientific”, or the “Company”), a medical research company with clinics providing innovative ketamine

Plexium, Inc. announced the appointment of Michael Martin, Ph.D. as President and Chief Executive Officer, and a member of the Board of Directors.

Tarsier Pharma, Ltd. today announced it has received agreement from the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA).

Device Solutions AB formerly Promore Pharma AB, carried out the reverse acquisition with the PMD group by decision of the extraordinary general meeting on 29 December 2023 and simultaneously decided on a reverse share split.

Virica Biotech Inc., a leading developer of cell enhancers for scaling of viral vector as well as cell and gene therapy manufacturing will expand its bioprocessing services through a partnership with Carleton University.

Vertex Announces US FDA Approval of CASGEVY ™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia.

Nurix Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for NX-5948, a highly selective degrader of Bruton’s tyrosine kinase (BTK), for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia.

Omnicell to Release Fourth Quarter and Full Year 2023 Financial Results on February 8, 2024.